.AN2 Therapies is reconsidering its service in reaction to poor midphase data, pledging to give up half its staff members and quit a phase 3
Read moreALX’s fizzling CD47 action rate delivers sell spiraling down
.ALX Oncology’s stage 2 stomach cancer response fee has deteriorated. After observing its CD47 blocker easily hammered control over the very first half of the
Read moreAC Immune views ‘landmark’ possible in Alzheimer’s drug information
.After greater than two decades of work with neurodegenerative diseases, Swiss biotech hvac Immune insurance claims it can have a game changer on its hands.The
Read more